IDH1 and central nervous system cancer: Blockade experiments revealed that combining CD47 inhibitor RRx‐001 with IDH1‐R132H inhibitor ivosidenib synergistically enhances TAM phagocytosis and glioma clearance, offering a novel combinatorial strategy [96].